MiNK Therapeutics, Inc.

INKT Nasdaq CIK: 0001840229

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 149 FIFTH AVENUE, NEW YORK, NY, 10010
Mailing Address 149 FIFTH AVENUE, NEW YORK, NY, 10010
Phone 212-994-8250
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events March 31, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
3 Initial insider ownership report March 23, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4/A Insider transaction amendment January 14, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC

Annual Reports

10-K March 31, 2026
  • Lead program agenT-797 demonstrated a 70% survival rate in ventilator patients with severe viral pneumonia.
  • Early clinical trials for solid tumors showed disease stabilization or shrinkage for over six months.
View Analysis

Insider Trading

SELL 1 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.